Genome Canada Annual Report 2016-17 20 National and international partnerships are powerful mecha- nisms that allow us to have global impact. Here are some highlights from the 2016-17 fiscal year. • The 2015 E-Rare-3 Joint Transnational Call: Translational Research Projects on Rare Diseases – This unique program enables collaboration on a translational level that contributes to achieving ambitious international goals to deliver new thera- pies and diagnostic tests for rare diseases in the coming years. Genome Canada is pleased to be working with five Canadian partners and various organizations from countries in the European Union in support of the program. The three genomics- related projects within the initiative focus on harmonizing phenomics information, improving the diagnosis and treatment of a cardiac arrhythmia syndrome, and studying a life-threaten- ing autosomal skin disease to understand its pathophysiology, facilitating the development of targeted therapies. • Structural Genomics Consortium – This public–private partnership supports the discovery of new medicines through open access research. Genome Canada contin- ues its support for the Structural Genomics Consortium, which is demonstrating that open science leads to socio-economic impacts. In fact, the Structural Genomics Consortium has partnered with the Montreal Neurological Institute and Hospital as they work to expand the impact of brain research and become the first Open Science Institute in the world. Partnerships are foundational to all our corporate programs and activities. We establish them upfront both as part of program design and development, as well as a requirement in all the projects we support. CONNECT